Literature DB >> 17443229

Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels.

S Rafiq1, K Stevens, A J Hurst, A Murray, W Henley, M N Weedon, S Bandinelli, A M Corsi, J M Guralnik, L Ferruci, D Melzer, T M Frayling.   

Abstract

Interleukin-1-receptor antagonist (IL-1RA) modulates the biological activity of the proinflammatory cytokine interleukin-1 (IL-1) and could play an important role in the pathophysiology of inflammatory and metabolic traits. We genotyped seven single nucleotide polymorphisms (SNPs) that capture a large proportion of common genetic variation in the IL-1RN gene in 1256 participants from the Invecchiare in Chianti study. We identified five SNPs associated with circulating IL-1RA levels with varying degrees of significance (P-value range=0.016-4.9 x 10(-5)). We showed that this association is likely to be driven by one haplotype, most strongly tagged by rs4251961. This variant is only in weak linkage disequilibrium (r(2)=0.25) with a previously reported variable number of tandem repeats polymorphism (VNTR) in intron-2 although a second variant, rs579543, that tags the VNTR (r(2)=0.91), may also be independently associated with IL-1RA levels (P=0.03). We found suggestive evidence that the C allele at rs4251961 that lowers IL-1RA levels is associated with an increased IL-1beta (P=0.03) level and may also be associated with interferon -gamma (P=0.03), alpha-2 macroglobulin (P=0.008) and adiponectin (P=0.007) serum levels. In conclusion, common variation across the IL-1RN gene is strongly associated with IL-1RA levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17443229     DOI: 10.1038/sj.gene.6364393

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  35 in total

Review 1.  The role of cytokines in breast cancer development and progression.

Authors:  Marcela Esquivel-Velázquez; Pedro Ostoa-Saloma; Margarita Isabel Palacios-Arreola; Karen E Nava-Castro; Julieta Ivonne Castro; Jorge Morales-Montor
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

2.  Association between the IFN-γ and IL-1 genetic polymorphisms and colorectal cancer in the Chinese Han population.

Authors:  Bao-Ying Fei; Huo-Xiang Lv; Yong-Wei Cheng; Jiang-Ming Yang
Journal:  J Genet       Date:  2014-04       Impact factor: 1.166

Review 3.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.

Authors:  Luigi Ferrucci; Elisa Fabbri
Journal:  Nat Rev Cardiol       Date:  2018-09       Impact factor: 32.419

4.  Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease.

Authors:  Luca Liberale; Fabrizio Montecucco; Jean-Claude Tardif; Peter Libby; Giovanni G Camici
Journal:  Eur Heart J       Date:  2020-08-14       Impact factor: 29.983

5.  Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation.

Authors:  Alexander P Reiner; Mark M Wurfel; Leslie A Lange; Christopher S Carlson; Alex S Nord; Cara L Carty; Mark J Rieder; Cindy Desmarais; Nancy S Jenny; Carlos Iribarren; Jeremy D Walston; O Dale Williams; Deborah A Nickerson; Gail P Jarvik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-01       Impact factor: 8.311

6.  Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes.

Authors:  S Rafiq; D Melzer; M N Weedon; H Lango; R Saxena; L J Scott; C N A Palmer; A D Morris; M I McCarthy; L Ferrucci; A T Hattersley; E Zeggini; T M Frayling
Journal:  Diabetologia       Date:  2008-10-14       Impact factor: 10.122

7.  Variable number of tandem repeat polymorphisms of the interleukin-1 receptor antagonist gene IL-1RN: a novel association with the athlete status.

Authors:  Sabina Cauci; Manuela Di Santolo; Kelli K Ryckman; Scott M Williams; Giuseppe Banfi
Journal:  BMC Med Genet       Date:  2010-02-22       Impact factor: 2.103

Review 8.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

9.  Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Jan A Ehses; Marc Y Donath; Thomas Mandrup-Poulsen
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

10.  Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations.

Authors:  Mukundan Attur; Hwa-Ying Wang; Virginia Byers Kraus; Jack F Bukowski; Nazneen Aziz; Svetlana Krasnokutsky; Jonathan Samuels; Jeffrey Greenberg; Gary McDaniel; Steven B Abramson; Kenneth S Kornman
Journal:  Ann Rheum Dis       Date:  2009-11-23       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.